Compare TPCS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | LSTA |
|---|---|---|
| Founded | 1956 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 28.9M |
| IPO Year | 2008 | 2000 |
| Metric | TPCS | LSTA |
|---|---|---|
| Price | $5.26 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 23.6K | ★ 310.7K |
| Earning Date | 02-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $31,644,000.00 | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $2.88 | $0.99 |
| 52 Week High | $6.31 | $5.07 |
| Indicator | TPCS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 45.82 |
| Support Level | $5.12 | $1.33 |
| Resistance Level | $5.69 | $2.06 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 9.30 | 8.62 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.